Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 28:13:26.
doi: 10.3389/fnmol.2020.00026. eCollection 2020.

TDP-43: From Alzheimer's Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy

Affiliations

TDP-43: From Alzheimer's Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy

Wendi Huang et al. Front Mol Neurosci. .

Abstract

Since the discovery of TAR DNA-binding protein 43 (TDP-43) in 1995, our understanding of its role continues to expand as research progresses. In particular, its role in the pathogenesis of Alzheimer's disease (AD) has drawn increasing interest in recent years. TDP-43 may participate in various pathogenic mechanisms underlying AD, such as amyloid β deposition, tau hyperphosphorylation, mitochondrial dysfunction, and neuroinflammation. Because AD is complex and heterogeneous, and because of the distinct characteristics of TDP-43, mostly seen in the oldest-old and those with more severe clinical phenotype, subcategorization based on specific features or biomarkers may significantly improve diagnosis and treatment. AD-like cognitive dysfunction associated with TDP-43 pathology may therefore be a distinct encephalopathy, referred to as limbic-predominant age-related TDP-43 encephalopathy (LATE).

Keywords: Alzheimer’s disease; LATE; LATE-NC; TDP-43; cognitive dysfunction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TAR DNA-binding protein 43 (TDP-43) : from Alzheimer’s disease (AD) to limbic-predominant age-related TDP-43 encephalopathy (LATE).

References

    1. Adams B. (2016). TauRx Misses Primary Endpoints in Alzheimer’s Combo PhIII Trial [Online]. Available online at: https://www.fiercebiotech.com/biotech/taurx-misses-primary-endpoints-alz.... Accessed July 27, 2016.
    1. Alzheimer’s Disease International (2018). World Alzheimer Report 2018—The state of the Art of Dementia Research: New Frontiers [Online]. Available online at: https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf. Accessed September 21, 2018.
    1. Amador-Ortiz C., Lin W. L., Ahmed Z., Personett D., Davies P., Duara R., et al. (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann. Neurol. 61, 435–445. 10.1002/ana.21154 - DOI - PMC - PubMed
    1. Arai T. (2014). Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology 34, 578–588. 10.1111/neup.12138 - DOI - PubMed
    1. Atri A., Frölich L., Ballard C., Tariot P. N., Molinuevo J. L., Boneva N., et al. (2018). Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA 319, 130–142. 10.1001/jama.2017.20373 - DOI - PMC - PubMed

LinkOut - more resources